AstraZeneca lays out $360M for 'next-gen' manufacturing plant in Dublin

As AstraZeneca works to incorporate Alexion following its major buyout, the company is already breaking out its checkbook to invest in next-gen manufacturing capacity.

On Tuesday, the U.K. drugmaker unveiled a $360 million investment at Alexion's campus in Dublin, where it'll construct an API facility for small molecules. The site will assist the company's global manufacturing network in late-stage development and supply early commercial supplies for certain medicines.